News & Updates

Asivatrep cream improves clinical signs and symptoms of atopic dermatitis without causing worrying adverse events, reports a recent study.

PF-06826647, a novel tyrosine kinase 2 inhibitor in development, outperforms placebo at reducing disease severity in patient with moderate-to-severe plaque psoriasis, reveals a new trial.

Ritlecitinib and brepocitinib lead to improvements in scalp alopecia areata and its associated biomarkers, reveals a recent substudy of a phase 2a trial.

Use of microneedling appears to be a beneficial adjunct to topical medications in the treatment of melasma, suggests a recent study.

Rescue therapy using the Janus kinase 1 inhibitor abrocitinib combined with topical medicated therapy recaptured efficacy responses and had a favourable safety profile in individuals with moderate-to-severe atopic dermatitis (AD) who experienced flare during the maintenance period of the phase III randomized-withdrawal JADE REGIMEN trial.

Use of antihypertensive medications is associated with the incidence of psoriasis, reports a study. Beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers (CCBs), and thiazide diuretics result in an increased risk of psoriasis.

In the treatment of patients with psoriasis, the combination of adalimumab plus methotrexate is more beneficial than adalimumab alone, reducing antidrug antibody formation and inducing slightly better response, drug survival, and higher serum trough concentrations, according to a study.

Upadacitinib with topical corticosteroids shows good long-term efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD), reports a recent follow-up analysis to the AD Up study.